

Table of Contents

Dr. McCarthy’s Credentials	5
Intended Audience	6
Outline of This Presentation.....	7
Learning Objectives of This Presentation	8
Problems FDA is Solving With Its Efforts About Adaptive Design	9
Overview and Disadvantages of Adaptive Design	10
Common Study Design Terms Not Used in the Adaptive Design Guidance.....	11
Improving Patient Recruitment – How Adaptive Design Can Help	12
Controlling Type 1 Error is Vital to FDA	13
Overview of Adaptive Design, Bayesian Statistical Analysis and Classical Statistical Analysis.....	14
How to Interpret a Guidance	15
Nine Study Design Modification Possible With An Adaptive Design.....	16
Three Reasons Why Definitions Are Important.....	17
FDA’s Definition of Adaptive Design	18
FDA’s Definition of Prospective	19
FDA’s Definition of Interim Analysis.....	20
FDA’s Emphasis on the Phrase, Adequate and Well-Controlled (A&WC) Study	21
FDA’s Definition of Exploratory Study	23
FDA’s Definition of a Reactive Revision	24
FDA’s Problems With a Reactive Revision	25
Eliminating Statistical Bias and Blinding Are Key Issues	26
Bias and Difficult to Interpret Positive Results Are General Concerns FDA Has With Adaptive Design	27
Blinding is a “Deal Breaker” for FDA Regarding Adaptive Design	28
Knowing When Adaptive Design is a Poor Choice or a Good Choice	29
When FDA Recommends Using Exploratory Studies.....	30
Features of Adaptive Designs Favored by FDA.....	31
Model SOP 1 of 2 - Blinding.....	32

Model SOP 2 of 2 – Data Monitoring Committee	33
Analyze Baseline Data To Improve Study Enrollment - Adaptive Design #1 of 5 Favored by FDA.....	34
Increase Sample Size Using Blinded Data - Adaptive Design #2 of 5 Favored by FDA.....	35
Increase Sample Size Using Blinded Data – Three Warnings.....	36
Delete Treatments After Interim Safety Data Analysis Unrelated to Efficacy - Adaptive Design #3 of 5 Favored by FDA.....	37
Early Study Termination Due to Either Lack of Benefit or Robust Evidence of Efficacy - Adaptive Design #4 of 5 Favored by FDA.....	38
Early Study Termination Due to Either Lack of Benefit or Robust Evidence of Efficacy - Adaptive Design #4 of 5 Favored by FDA (page 2)	39
Definition of Group Sequential Design.....	40
Changing a Statistical Analysis Plan Late in a Study - Adaptive Design #5 of 5 Favored by FDA.....	41
Definition of Statistical Analysis Plan (SAP)	42
Safety Data and Adaptive Design – Possible Problems	43
Adaptive Design Is Not a Fit For Special Protocol Assessment (SPA).....	44
Feedback From FDA About Your Planned Adaptive Design	45
Questions for Bill McCarthy - Insight into Adaptive Design Evaluation and Use.	46
Checklist for a Successful Adaptive Design Study	47
Summary of Key Ideas From This Audioconference	49
Next Steps For Implementing Adaptive Design	50
Joshua Sharlin, Ph.D., Resume.....	51